ENDRA Life Sciences Inc.

Name: ENDRA Life Sciences Inc. standardized financial statements, quarterly
Creator: Listed

NDRANasdaqCIK 1681682HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Operating income−$1.5m, Q2 FY2026

Net income$159.9k, Q2 FY2026

ENDRA Life Sciences Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$k	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Cost of revenue	$k	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Gross profit	$k	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Research and development	$k	1,633	579	1,042	716	794	638	529	381	432	508	776	234
Operating income	$k	(3,129)	(1,458)	(2,781)	(2,231)	(1,509)	(4,297)	(1,469)	(1,301)	(1,371)	(1,622)	(2,174)	(1,483)
Interest expense	$k	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Income tax	$k	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	not reported	not reported	not reported	not reported
Net income	$k	(3,101)	(1,460)	(2,776)	(2,229)	(2,354)	(4,149)	(1,036)	(1,226)	(1,596)	(3,169)	(1,311)	160
Diluted EPS	$ per share	not reported	not reported	not reported	not reported	(9.54)	not reported	(1.86)	(1.71)	(2.10)	not reported	(1.09)	0.06
Basic EPS	$ per share	not reported	not reported	not reported	not reported	(9.54)	not reported	(1.86)	(1.71)	(2.10)	not reported	(1.09)	0.12

Balance sheet

Cash and equivalents$1.7m, Q2 FY2026

Long-term debt$0, FY2024

Shareholders' equity$6.3m, Q2 FY2026

ENDRA Life Sciences Inc., balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	not reported	not reported	not reported	not reported	not reported	3.2	not reported	1.8	0.8	0.8	0.4	1.7
Current assets	$m	6.4	3.0	1.3	6.7	5.0	3.4	2.2	1.9	1.0	1.0	0.5	5.6
Total assets	$m	7.6	6.8	5.1	10.4	8.4	4.5	3.2	2.8	2.0	3.9	3.4	7.9
Current liabilities	$m	2.2	0.9	1.2	1.4	0.8	0.6	0.6	0.6	0.8	0.8	0.8	0.8
Total liabilities	$m	2.4	1.1	1.4	1.4	1.8	1.9	1.4	1.3	1.8	1.6	1.7	1.6
Long-term debt	$m	not reported	0.0	0.0	not reported	not reported	0.0	not reported	not reported	not reported	not reported	not reported	not reported
Short-term borrowings	$m	0.0	0.0	0.0	0.0	0.0	0.0	not reported	not reported	not reported	not reported	not reported	not reported
Shareholders' equity	$m	5.2	5.7	3.7	9.0	6.6	2.6	1.8	1.5	0.2	2.3	1.8	6.3

Cash flow

Operating cash flow−$927.6k, Q2 FY2026

Capital expenditure$0, Q4 FY2025

ENDRA Life Sciences Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$k	(2,599)	(2,175)	(2,144)	(2,083)	(1,657)	(1,516)	(1,293)	(1,114)	(1,164)	(1,612)	(1,120)	(928)
Capital expenditure	$k	0.0	6.9	27.0	(11.0)	0.0	0.0	17.3	0.0	0.0	0.0	not reported	not reported
Dividends paid	$k	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported

Diluted shares (weighted)2.48m, Q2 FY2026

ENDRA Life Sciences Inc., shares, quarterly
Line item	Unit	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	k shares	247	558	717	761	1,200	2,475

Shares outstanding: 1.50m at Aug 14, 2026, from the cover of the 10-Q filed Aug 14, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:46 ET. Listed shows no prices and gives no investment advice.